Leiden, Utrecht October 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid models on a Chip. The agreement includes a license to MIMETAS to market HUB Organoids in an assay ready format, as well as a collaborative effort to develop disease-specific models.
The second annual BHCR Investment Conference, which is an invitation-only event, will be held at AstraZeneca in Gaithersburg on October 15 and 16, 2019.
BioHealth Innovation (BHI), J.P. Morgan, Wilson Sonsini Goodrich & Rosati (WSGR), Deloitte, AstraZeneca and The Maryland Department of Commerce have worked closely to ensure the 2019 investment conference builds on the success of last year’s event.
Image: https://biobuzz.io
The National Institutes of Health has awarded $20 million to fund five additional hubs designed to speed up the translation of biomedical discoveries into commercially viable diagnostics, devices, therapeutics, and tools to improve patient care and enhance health. The newly selected Research Evaluation and Commercialization Hubs (REACH) expand a national network of proof-of-concept centers that links 34 academic institutions developing best practices to translate biomedical innovations into public benefit.
The National Institute on Drug Abuse (NIDA) awarded Emergent BioSolutions a $6.3 million research grant for further development of the company’s treatment for opioid addiction.
Specifically, the funding is for the continued development of AP007, Emergent’s sustained-release nalmefene formulation for the treatment of addiction in opioid use disorder (OUD). AP007 is designed to continually release an effective dose of nalmefene for up to three months and to be administered through intramuscular injection.
Attracting talent is one of the most commonly cited challenges voiced by company executives in the Biohealth Capital Region (BHCR). Rapid growth, particularly in the cell and gene therapy industry and advanced biomanufacturing, is applying strong pressure on companies that are up against a finite market with a skills gap, talent shortages and other regional recruiting challenges.
Image: https://biobuzz.io
The Federal Laboratory Consortium (FLC) for Technology Transfer Mid-Atlantic Region is pleased to announce the following winners of its 2019 awards:
We are pleased to announce that Dr. Monica Lopez will receive from the President of Johns Hopkins University and the Johns Hopkins Alumni Association the prestigious Outstanding Recent Graduate Award for bringing credit to Johns Hopkins University through outstanding professional achievements, leadership, and vision.
Image: http://www.lpnproductions.com
GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) — Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia. The Series B will also fund earlier stage ARC-T + sparX programs for patients with solid tumors and diseases outside oncology.
Partnerships with consumer-tech firms could help medtech companies innovate and stay relevant as healthcare turns increasingly to prevention and wellness, according to a new report from Deloitte.
Executives at medtech companies may be leery of Apple and other consumer-technology companies, especially as the latter tout ever-more-sophisticated healthcare applications. But as healthcare evolves, those potential competitors may turn out to be good partners, according to a new report by accounting and consulting firm Deloitte.
The ribbon was cut today at GSK’s recently expanded manufacturing facility in Rockville, marking the completion of a $139M project that was first announced in May 2017 to support growing demand for BENLYSTA® (belimumab), a treatment for adult patients with Lupus.
Image: https://biobuzz-io.cdn.ampproject.org
